Geneva, Switzerland (PRWEB) March 08, 2013
Geneva, Switzerland (PRWEB) March 8, 2013 – Selexis SA announced today the Company’s vice president of business development, Armelle Gaussin, Ph.D., will present, “Proprietary and Unique Expression System for Versatile and Ubiquitous Transgene Expression” as part of the Cell Therapy/Regenerative Medicine Track on Tuesday, March 12, 2013 at 3:30 PM at the BIO-Europe Spring 2013 Partnering Conference being held March 11 – 13, 2013 at the Centre Covencions Internacional Barcelona (CCIB), in Barcelona, Spain. The Company will be also taking part in the pre-scheduled partnering meetings.
Selexis has developed a full expression platform based on proprietary epigenetic regulator elements, the Selexis Genetic Elements, enabling versatile and ubiquitous transgene expression in mammalian cells. This expression system has a wide range of application areas. In the cell therapy field, high and stable transgene expression is obtained in adult stem cells and also sustained upon cell differentiation both in vitro and in vivo. The platform also provides a simple, fast and reliable approach towards stable cell line development for the production of therapeutic proteins and offers a dedicated approach for difficult to express proteins.
Companies or individuals attending BIO-Europe Spring can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bes/index.php
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.
Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information: